US · XENE
Xenon Pharmaceuticals Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Burnaby, BC V5G 4W8
- Website
- xenon-pharma.com
Price · as of 2025-12-31
$56.13
Market cap 3.34B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | $18.29 | -67.41% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $9.28 | $126.30 | |||
| 2014 | $18.35 | $140.07 | $6.92 | $9.93 | $11.03 |
| 2015 | $7.49 | $6,265.62 | $3.62 | $0.00 | $38.51 |
| 2016 | $8.35 | $30.00 | $2.27 | $0.00 | $113.44 |
| 2017 | $4.50 | $24.78 | $0.03 | $0.00 | $121.33 |
| 2018 | $9.19 | $29.97 | |||
| 2019 | $14.18 | $2.19 | $0.00 | ||
| 2020 | $20.55 | $113.23 | $300.23 | $0.79 | $0.00 |
| 2021 | $28.98 | $32.95 | $10.38 | $3.57 | $58.98 |
| 2022 | $34.18 | $35.16 | $9.26 | $1.56 | $79.83 |
| 2023 | $46.24 | $41.00 | |||
| 2024 | $36.50 | ||||
| 2025 | $42.55 | $2.12 | $0.00 |
AI valuation
Our deep-learning model estimates Xenon Pharmaceuticals Inc.'s (XENE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $56.13
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$18.29
-67.41% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XENE | Xenon Pharmaceuticals Inc… | $56.13 | 3.34B | — | -67% | — | — | -9.75 | 5.80 | 449.63 | -8.27 | -21.74 | 5.80 | 66.09% | -4974.27% | -4612.13% | -51.76% | -419.58% | -48.34% | 0.01 | — | 13.13 | 13.17 | 0.56 | 4485.00% | — | 5175.00% | -8.30% | -6.68 | -314.81% | 0.00% | 0.00% | 1.71% | -7.59 | -10.11 | 377.51 | 35.64 |
| AAPG | ASCENTAGE PHARMA GROUP IN… | $24.00 | 557.78M | -51% | -67% | — | — | -27.16 | 40.63 | 10.95 | -46.99 | — | 65.65 | 97.03% | -37.70% | -41.34% | -243.53% | -49.87% | -15.45% | 6.32 | -5.74 | 1.26 | 1.14 | -1.82 | -8979.00% | 34177.00% | -8267.00% | -1.26% | -0.10 | -18.30% | 0.00% | 0.00% | 2.74% | -30.20 | -82.32 | 11.39 | -0.29 |
| APGE | Apogee Therapeutics, Inc. | $70.00 | 3.84B | — | — | — | — | -10.95 | 2.78 | — | -6.86 | -11.08 | 2.78 | 0.00% | — | — | -33.22% | -223.05% | -31.53% | 0.02 | — | 18.55 | 18.39 | 0.60 | 9880.00% | — | 12999.00% | -8.64% | -5.99 | -177.24% | 0.00% | 0.00% | 0.69% | -6.85 | -8.62 | — | 31.49 |
| CELC | Celcuity Inc. | $111.71 | 5.17B | — | — | — | — | -3.76 | 3.63 | — | -2.79 | -72.15 | 3.63 | 0.00% | — | — | -87.54% | 909.82% | -51.23% | 0.85 | -11.02 | 7.71 | 7.46 | -0.74 | 520.00% | — | 5529.00% | -19.94% | -2.63 | 672.45% | 0.00% | 0.00% | 0.00% | -2.49 | -3.38 | — | -0.09 |
| CGON | CG Oncology, Inc. Common … | $58.80 | 4.74B | +6% | +153% | — | — | -27.73 | 5.93 | 1105.21 | -23.38 | -58.37 | 6.02 | -15.02% | -4722.13% | -3985.02% | -21.67% | -4199.76% | -20.82% | 0.01 | — | 24.63 | 24.09 | 0.16 | 4752.00% | 25470.00% | 6781.00% | -2.97% | -4.29 | -2916.46% | 0.00% | 0.00% | 0.00% | -19.55 | -28.15 | 923.25 | 68.35 |
| CNTA | Centessa Pharmaceuticals … | $26.86 | 3.61B | +34% | — | — | — | -7.88 | 4.63 | — | -6.73 | -25.25 | 4.63 | 0.00% | — | — | -73.93% | -398.61% | -50.32% | 0.29 | -19.93 | 9.25 | 9.09 | 1.20 | 3121.00% | -10000.00% | -1148.00% | -7.65% | -2.45 | -281.71% | 0.00% | 0.00% | 11.98% | -7.43 | -10.51 | — | 3.81 |
| LEGN | Legend Biotech Corporatio… | $19.00 | 1.75B | +139% | +396,718% | -91% | — | -20.39 | 3.10 | 5.14 | -21.66 | — | 3.72 | 62.60% | -48.35% | -28.22% | -13.80% | -112.36% | -8.99% | 0.34 | -14.03 | 4.62 | 4.49 | -0.56 | -6701.00% | 11997.00% | -6199.00% | -4.91% | -0.52 | -58.59% | 0.00% | 0.00% | 0.00% | -8.08 | -15.50 | 3.91 | 2.18 |
| RARE | Ultragenyx Pharmaceutical… | $23.39 | 2.26B | -15% | -61% | — | — | -3.95 | -28.37 | 3.37 | -5.71 | — | -7.57 | 83.80% | -79.49% | -85.44% | -656.03% | -567.31% | -37.89% | -15.95 | -8.63 | 2.48 | 2.22 | -1.68 | -731.00% | 2013.00% | 1193.00% | -20.80% | -1.21 | -500.50% | 0.00% | 0.00% | 0.00% | -5.33 | -6.04 | 4.24 | -3.56 |
| SRRK | Scholar Rock Holding Corp… | $44.27 | 4.52B | — | — | — | — | -14.59 | 9.75 | — | -13.57 | -60.50 | 9.81 | 0.00% | — | — | -82.95% | -14081.23% | -62.67% | 0.18 | -36.87 | 9.61 | 9.36 | 0.47 | 2412.00% | — | 3837.00% | -5.59% | -4.28 | -11231.68% | 0.00% | 0.00% | 2.02% | -12.78 | -16.03 | — | 16.84 |
| TVTX | Travere Therapeutics, Inc… | $29.79 | 2.67B | +90% | +51,751% | — | — | -103.12 | 22.94 | 5.37 | 118.84 | — | 2744.19 | 85.51% | -12.80% | -10.24% | -29.38% | -59.63% | -4.26% | 2.86 | -5.85 | 2.74 | 2.52 | 10.61 | -8627.00% | 11045.00% | -11116.00% | 1.43% | 0.24 | 35.86% | 0.00% | 0.00% | 4.07% | -42.03 | 69.88 | 5.38 | 0.84 |
| ZLAB | Zai Lab Limited | $19.22 | 2.13B | +50% | -49% | — | — | -11.49 | 2.82 | 4.38 | -9.81 | — | 3.16 | 58.60% | -49.86% | -38.15% | -22.56% | -97.09% | -14.89% | 0.31 | -44.05 | 2.45 | 1.91 | 2.88 | -3846.00% | 1533.00% | -4251.00% | -7.88% | -0.36 | -68.36% | 0.00% | 0.00% | 7.89% | -6.77 | -9.77 | 3.37 | -0.13 |
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
- CEO
- Ian C. Mortimer
- Employees
- 316
- Beta
- 0.96
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($18.29 ÷ $56.13) − 1 = -67.41% (DCF, example).